CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
QH104 Cell injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06592092
NCT06592092N/ACompleted
CompareCT.gov

Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences·interventional·Posted Sep 19, 2024·Updated Jan 29, 2026

In Brief

A clinical study evaluating QH104 Cell injection for Solid Tumor and Meningeal Metastasis. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This is an open, single-arm, single-center, interventional clinical study. It is planned to enroll 3-6 patients with meningeal metastases from B7H3+ solid tumors and to explore, on a small scale, the efficacy of local injection of allogeneic B7H3 CAR-γδ T cells (3\*107/dose) for the treatment of patients with meningeal metastases from B7H3+ solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Meningeal Metastasis
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20252026
First PostedSep 19, 2024
Enrollment StartApr 1, 2024
Primary CompletionMay 31, 2025
Study CompletionJan 28, 2026
TodayJul 1, 2026
Enrollment to primary: 1.2 yearsPosted 1.8 years ago

Interventions

QH104 Cell injectionbiological

Patients will first be pre-screened for B7H3 expression of tumor and exist Meningeal Metastases.